Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on: December 20,2023

Scientists unveil chemotherapy resistance mechanism related to p53 mutation

by Instituto Nacional de Ciência e Tecnologia de Biologia Estrutural e Bioimagem (INBEB)Comparison between the response of tumoral cells to chemotherapy with no mutation of p53 (upper cells) and of mu

Updated on:December 20,2023

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on: October 24,2023

CHMP Recommends Against Renewal of Marketing Authorization for Belantamab Mafodotin in R/R Myeloma

September 18, 2023Chris RyanThe European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended against renewal of the conditional marketing authorization for belantamab maf

Updated on:October 24,2023

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on: December 21,2023

Splicing deregulation detected and targeted in type of childhood leukemia

byUniversity of California - San DiegoA micrograph depicts acute myeloid leukemia cells. Though treatments have dramatically advanced, AML in children can become resistant to therapy. New resear

Updated on:December 21,2023

The phenotypic plasticity effect of cancer cells and how to exploit it

by Michael Hesse,Max Planck SocietyMathematical model of tumor heterogeneity and phenotype switching: A detailed analysis. Credit: M.Raatz, MPI for Evolutionary BiologyCancer cells are notorious

Updated on: October 31,2023

The phenotypic plasticity effect of cancer cells and how to exploit it

by Michael Hesse,Max Planck SocietyMathematical model of tumor heterogeneity and phenotype switching: A detailed analysis. Credit: M.Raatz, MPI for Evolutionary BiologyCancer cells are notorious

Updated on:October 31,2023

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on: October 24,2023

Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL

June 12, 2021Conor KillmurrayIn the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large

Updated on:October 24,2023

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on: October 24,2023

Tumor Sequencing Identifies Host Signatures Tied to Immunotherapy Response in Advanced RCC

July 14, 2023Caroline SeymourHigher levels of baseline TCR clonality in peripheral blood mononuclear cells (PBMCs) and baseline IgG1 fraction in PBMCs and tumor tissue were identified in an institutio

Updated on:October 24,2023

FDA approves CAR T cell treatment for resistant mantle cell lymphoma

by Jim Stallard,Memorial Sloan Kettering Cancer CenterCredit: Pixabay/CC0 Public DomainMantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatme

Updated on: August 27,2024

FDA approves CAR T cell treatment for resistant mantle cell lymphoma

by Jim Stallard,Memorial Sloan Kettering Cancer CenterCredit: Pixabay/CC0 Public DomainMantle cell lymphoma (MCL) is a rare and sometimes ruthless form of non-Hodgkin lymphoma. Even when treatme

Updated on:August 27,2024

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on: October 24,2023

Sunitinib Elicits Improved Efficacy Vs Placebo in Malignant Pheochromocytoma/Paragangliomas

September 20, 2021Kristie L. KahlFirst-line sunitinib was found to improve efficacy compared with placebo in patients with malignant pheochromocytoma and paragangliomas.First-line sunitinib (Sut

Updated on:October 24,2023

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on: October 15,2023

Is AI Ready to Play a Leading Role in Colorectal Cancer Screening?

by Sharon ReynoldsArtificial intelligence, or AI, is suddenly everywhere. From ChatGPT to automated customer service "representatives,” the ability of computers to perform increasingly complicate

Updated on:October 15,2023

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on: October 17,2023

Maveropepimut-S Plus Pembrolizumab and Cyclophosphamide Shows Early Promise in R/R DLBCL

February 13, 2023Kristi RosaThe combination of maveropepimut-S, pembrolizumab, and intermittent low-dose cyclophosphamide elicited responses in patients with relapsed or refractory diffuse large B-cel

Updated on:October 17,2023

Out-of-pocket costs for cancer care keep climbing

Cancerpatients already have a lot to deal with emotionally and physically. But research shows that insured patients under 65 are also paying more for their treatments out-of-pocket than ever bef

Updated on: December 18,2023

Out-of-pocket costs for cancer care keep climbing

Cancerpatients already have a lot to deal with emotionally and physically. But research shows that insured patients under 65 are also paying more for their treatments out-of-pocket than ever bef

Updated on:December 18,2023

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on: November 02,2023

Comparing DNA changes in blood stem cells and leukemia cells could help pick out children with high-risk AML

Credit: Unsplash/CC0 Public DomainIn some children with acute myeloid leukemia, cancer cells have as many DNA changes as healthy blood stem cells. Researchers were surprised to find these children hav

Updated on:November 02,2023